F. Ranchon, C. Bouret, B. Charpiat, and G. Leboucher, S??curisation de l???emploi des chimioth??rapies anticanc??reuses administrables par voie orale, Le Pharmacien Hospitalier, vol.44, issue.1, pp.36-44, 2009.
DOI : 10.1016/j.phhp.2008.12.002

. Ligue-nationale-contre-le-cancer-http, ligue-cancer.net/article/le-cancer/qu-est-ce-que-le-cancer--septembre, 2009.

. La-situation-du-cancer-en-france-en, e-cancer.fr/les-soins/dispositif-d-annonce/outils-de-liaison-medecin? ide/doc_download/1285-la-situation-du-cancer-en, 2009.

G. Liu, E. Franssen, M. Fitch, and E. Warner, Patient preferences for oral versus intravenous palliative chemotherapy., Journal of Clinical Oncology, vol.15, issue.1, pp.110-115, 1997.
DOI : 10.1200/JCO.1997.15.1.110

M. Borner and P. Schsffski, A randomized crossover trial comparing oral UFT (uracil/tegafur)+leucoverin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer, Proc Am Soc Clin Oncol, vol.19, 2000.

A. Lebovits, J. Strain, and S. Schleifer, Patient noncompliance with self-administered chemotherapy, Cancer, vol.37, issue.1, pp.17-22, 1990.
DOI : 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I

J. Blum, The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer, The Oncologist, vol.6, issue.1, pp.56-64, 2001.
DOI : 10.1634/theoncologist.6-1-56

J. Douillard and P. Tilleul, Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting, Oncology, vol.72, issue.3-4, pp.248-254, 2007.
DOI : 10.1159/000113016

B. Singh and B. Malhotra, Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents, Clinical Pharmacokinetics, vol.123, issue.1, pp.1127-56, 2004.
DOI : 10.2165/00003088-200443150-00005

V. Schwiertz, C. Bertin, A. Henry, and B. Charpiat, Number and nature of drug interactions concerning antineoplasic drugs, Bull Cancer, vol.94, issue.5, pp.477-82, 2007.

K. Westphal, A. Weinbrenner, and M. Zschiesche, Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction, Clinical Pharmacology & Therapeutics, vol.68, issue.4, pp.345-355, 2000.
DOI : 10.1067/mcp.2000.109797

E. Gambillara, E. Laffite, and N. Widmer, Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia, Dermatology, vol.211, issue.4, pp.363-368, 2005.
DOI : 10.1159/000088510

T. Grenader, M. Gipps, L. Shavit, and A. Gabizon, Significant drug interaction: Phenytoin toxicity due to erlotinib, Lung Cancer, vol.57, issue.3, pp.404-410, 2007.
DOI : 10.1016/j.lungcan.2007.02.011

L. Simon, D. Prebay, and A. Beretz, Médecines complémentaires et alternatives suivies par les patients cancéreux de France, Bull Cancer, vol.94, issue.5, pp.483-491, 2007.

P. Smith, J. Bullock, B. Booker, C. Haas, C. Berenson et al., Induction of imatinib metabolism by hypericum perforatum, Blood, vol.104, issue.4, pp.1229-1259, 2004.
DOI : 10.1182/blood-2004-04-1240

J. Urquhart, Role of Patient Compliance in Clinical Pharmacokinetics, Clinical Pharmacokinetics, vol.27, issue.3, pp.202-217, 1994.
DOI : 10.2165/00003088-199427030-00004

G. Bonadonna and P. Valagussa, Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer, New England Journal of Medicine, vol.304, issue.1, pp.10-15, 1981.
DOI : 10.1056/NEJM198101013040103

C. Tebbi, M. Zevon, M. Richards, and K. Cumming, Attributions of responsibility in adolescent cancer patients and their parents, Journal of Cancer Education, vol.4, issue.2, pp.135-177, 1989.
DOI : 10.1080/08858198909527987

C. Tebbi, Treatment compliance in childhood and adolescence. Cancer, pp.3441-3450, 1993.

B. Hamburg and G. Inoff, Relationships Between Behavioral Factors and Diabetic Control in Children and Adolescents: A Camp Study, Psychosomatic Medicine, vol.44, issue.4, pp.321-360, 1982.
DOI : 10.1097/00006842-198209000-00002

W. Europe, Therapeutic patient education: continuing education programmes for healthcare providers in the field of prevention of chronic diseases, Copenhagen: WHO Europe, 1998.

D. Perol and P. Toutenu, L'éducation thérapeutique en cancérologie : vers une reconnaissance des compétences du patient, Bull Cancer, vol.94, issue.3, pp.267-74, 2007.

L. Nationale-contre-le-cancer, Cancer du sein : http://www.ligue-cancer.net/article/317_cancer-du-sein?gclid=CNLw0fmA7Z8CFR-Y2AodiDS0Xg - Février, 2010.

J. Eilers and R. Million, Prevention and management of oral mucositis in patients with cancer, seminars in oncology nursing, pp.201-212, 2007.

E. B. Rubenstein, D. E. Peterson, and M. Schubert, Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis, Cancer, vol.95, issue.S9, pp.2026-2046, 2004.
DOI : 10.1002/cncr.20163

C. Scully, S. Sonis, and P. Diz, Mucosal diseases series, oral diseases, pp.229-241, 2006.

S. Silverman, Diagnosis and management of oral mucositis, supportive oncology, pp.13-21, 2007.

D. M. Keefe, M. M. Schubert, and L. Elting, Updated clinical practice guidelines for the prevention and treatment of mucositis, cancer, pp.820-83, 2007.

E. Peterson, New strategies for management of oral mucositis in cancer patients, 2005, supportive oncology, pp.9-13, 2006.

H. V. Worthington, J. E. Clarkson, and O. Eden, Interventions for preventing oral mucositis for patients with cancer receiving treatment, cochrane database of systematic reviews, 2006.

J. E. Clarkson, H. V. Worthington, and O. Eden, Interventions for treating oral mucositis for patients with cancer receiving treatment, cochrane database of systematic reviews, 2007.

A. Barasch, S. Elad, A. Altman, K. Damato, and J. Epstein, Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis, support care cancer, pp.528-532, 2006.

S. Grober, R. Carpenter, and M. Glassman, A comparison of patients' perceptions of oral cancer treatments and intravenous cancer treatments: what the health care team needs to know, Proceedings of the American Society of Clinical Oncology, vol.22, p.746, 2003.

C. Catania, F. Didier, and A. Sbanotto, Fully oral chemotherapy regimens, patient's or physician's preference, Proceedings of the American Society of Clinical Oncology, vol.22, p.777, 2003.